Cargando…
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety
[Image: see text] The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we have developed a novel anticance...
Autores principales: | Borsari, Chiara, Rageot, Denise, Beaufils, Florent, Bohnacker, Thomas, Keles, Erhan, Buslov, Ivan, Melone, Anna, Sele, Alexander M., Hebeisen, Paul, Fabbro, Doriano, Hillmann, Petra, Wymann, Matthias P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792169/ https://www.ncbi.nlm.nih.gov/pubmed/31620236 http://dx.doi.org/10.1021/acsmedchemlett.9b00333 |
Ejemplares similares
-
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
por: Tarantelli, Chiara, et al.
Publicado: (2019) -
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017) -
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability
por: Borsari, Chiara, et al.
Publicado: (2021) -
Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses
por: Citarella, Andrea, et al.
Publicado: (2021) -
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
por: Hillmann, Petra, et al.
Publicado: (2019)